Recombinant Viola odorata Vodo peptide N

What are Vodo peptides and how were they discovered?

Vodo peptides are macrocyclic peptides isolated from Viola odorata L. (sweet violet), characterized by their unique structural topology containing a cyclic cystine knot motif. These peptides belong to the cyclotide family, which are known for their exceptional stability and diverse bioactivities. Recent research has identified several novel cyclotides from V. odorata, designated as Vodo P1 through Vodo P7 . These peptides were discovered through systematic isolation and characterization of cyclic peptides using liquid chromatography-tandem mass spectrometry (LC-MS/MS) followed by database searching and computational processing. The study of V. odorata petiole tissue revealed 47 precursor sequences that encoded for 15 previously reported cyclotides, 4 putative novel cyclotides, and 3 acyclotides .

What structural features define Vodo peptides?

Vodo peptides exhibit distinctive structural characteristics that contribute to their remarkable stability. These include:

• Six conserved cysteine residues forming three disulfide bonds in a knotted arrangement

• A cyclic peptide backbone (head-to-tail cyclization)

• Conserved Asp or Asn residues in loop 6, which are crucial for cyclization

• Variable loop regions between the conserved cysteine residues

• Classification into either Möbius or bracelet subfamilies based on structural features

The number of amino acid residues varies among different Vodo peptides, with some containing up to 33 amino acids, while others like those belonging to the Möbius family (kalata B2 and kalata S) contain 29 amino acid residues . This structural diversity contributes to their varied biological activities and potential applications.

How do Vodo peptides differ from other plant cyclotides?

While Vodo peptides share the core cyclotide structure with peptides from other plant species, they exhibit distinct sequence variations that may confer unique functional properties. Sequence alignment studies have revealed that Vodo peptides maintain the six conserved cysteine residues essential for the cyclic cystine knot motif, but show considerable variation in the intercysteine loops . Some cyclotides isolated from V. odorata have been found in other plant species but with different names, highlighting the lack of a standardized nomenclature system. For example, cyclotides like Mra5 and viba7, initially reported from Melicytus ramiflorus and V. baoshanensis respectively, have also been identified in V. odorata petiole tissue . This sequence diversity is visualized through sequence diversity wheels, which illustrate consensus amino acid residues and variations among different cyclotides.

What are the optimal methods for extracting and purifying Vodo peptides?

The extraction and purification of Vodo peptides involves a systematic approach that preserves their structural integrity while maximizing yield. Based on recent research protocols:

• Tissue Preparation: Collect fresh plant material (preferably petiole tissue) from V. odorata plants grown in natural habitats (optimal collection period: March-April) .

• Extraction: Utilize a dichloromethane/methanol extraction system followed by multiple rounds of solvent partitioning.

• Initial Purification: Employ solid-phase extraction using C18 columns with varying concentrations of acetonitrile for elution.

• High-Resolution Purification: Conduct reversed-phase high-performance liquid chromatography (RP-HPLC) with appropriate gradients.

• Confirmation: Verify purified fractions using analytical HPLC and mass spectrometry.

This extraction methodology has successfully yielded multiple cyclotides from V. odorata petiole tissue, including both known and novel Vodo peptides . For recombinant production, these naturally occurring sequences serve as essential templates.

How can LC-MS/MS be optimized for Vodo peptide identification?

LC-MS/MS plays a crucial role in the identification and characterization of Vodo peptides, requiring specific optimization parameters:

• Sample Preparation:

  • Enzymatic digestion with endoproteinases (e.g., trypsin, endoproteinase Glu-C)

  • Reduction and alkylation of disulfide bonds prior to analysis

• Chromatographic Separation:

  • C18 reversed-phase columns (typically 2.1 × 150 mm, 3.5 μm particle size)

  • Gradient elution with 0.1% formic acid in water and acetonitrile

  • Flow rates of 0.2-0.3 mL/min for optimal separation

• Mass Spectrometry Parameters:

  • Positive ion mode electrospray ionization

  • Full scan range of m/z 350-2000

  • Collision-induced dissociation with normalized collision energy of 35%

  • Data-dependent acquisition for automated MS/MS

• Data Analysis:

  • Processing against customized cyclotide databases

  • De novo sequencing for novel peptide identification

  • Manual verification of MS/MS spectra for cyclic peptide fragments

The MS/MS spectra obtained from petiole tissue extracts of V. odorata have successfully identified multiple peptide masses corresponding to various cyclotides, as demonstrated in recent research studies .

What computational approaches are most effective for analyzing Vodo peptide sequences?

Computational analysis of Vodo peptides requires specialized approaches due to their unique cyclic structure and conserved cysteine framework:

• Database Searching:

  • Utilize specialized cyclotide databases (e.g., CyBase)

  • Employ modified search algorithms that account for cyclic peptide fragmentation patterns

  • Implement error-tolerant searches to identify novel variants

• Sequence Alignment and Homology Assessment:

  • Multiple sequence alignment to identify conserved residues

  • Assessment of sequence similarity using BLAST with optimized parameters for short peptides

  • Protein diversity wheel analysis to visualize sequence variation

• Structural Prediction:

  • Homology modeling based on known cyclotide structures

  • Molecular dynamics simulations to assess stability and flexibility

  • Prediction of disulfide bond formation and cyclic peptide backbone

• Functional Annotation:

  • Machine learning approaches to predict bioactivity based on sequence features

  • Identification of conserved motifs associated with specific bioactivities

  • Structure-activity relationship analysis

These computational methods have successfully characterized diverse cyclotides from V. odorata, revealing significant sequence variations while maintaining the critical structural features that define this peptide class .

What expression systems are most suitable for recombinant Vodo peptide production?

The selection of an appropriate expression system is critical for successful recombinant production of Vodo peptides. Each system offers distinct advantages and limitations:

When expressing Vodo peptides recombinantly, researchers must carefully consider the structural complexity of these cyclotides, including the crucial disulfide bonding pattern and cyclic backbone. The expression strategy should incorporate appropriate fusion partners, optimized codon usage, and efficient cyclization mechanisms to produce functional peptides with native-like properties.

What are the key challenges in recombinant production of cyclized Vodo peptides?

Recombinant production of cyclized Vodo peptides presents several significant challenges due to their complex structural features:

• Cyclization Mechanism:

  • Achieving efficient head-to-tail cyclization requires specialized approaches

  • Intein-based methods can facilitate cyclization but may affect yield

  • Enzymatic cyclization using sortase or asparaginyl endopeptidase requires optimization

• Disulfide Bond Formation:

  • Correct formation of three disulfide bonds in the knotted arrangement is critical

  • Misfolding and incorrect disulfide pairing can lead to inactive products

  • Optimizing oxidative folding conditions is essential for native-like structure

• Expression Toxicity:

  • Some Vodo peptides may exhibit toxicity to the expression host

  • Tight regulation of expression and appropriate fusion partners can mitigate toxicity

  • Inducible promoters and secretory pathways help manage potential toxic effects

• Structural Verification:

  • Confirming correct cyclization and disulfide bonding is challenging

  • Multiple analytical techniques (MS/MS, NMR, enzymatic digestion) are required

  • Bioactivity assays serve as functional verification of proper folding

These challenges necessitate a multifaceted approach combining genetic engineering, optimized expression conditions, and sophisticated purification and characterization methods to produce authentic recombinant Vodo peptides.

How can yield and purity of recombinant Vodo peptides be optimized?

Optimizing the yield and purity of recombinant Vodo peptides requires strategic approaches across the entire production pipeline:

• Genetic Optimization:

  • Codon optimization for the selected expression host

  • Incorporation of efficient signal sequences for secretory expression

  • Selection of appropriate fusion partners (e.g., thioredoxin, SUMO) to enhance solubility

  • Incorporation of precision cleavage sites for fusion tag removal

• Expression Condition Optimization:

  • Temperature modulation (typically lower temperatures improve folding)

  • Induction timing and inducer concentration adjustment

  • Media composition modification to enhance disulfide bond formation

  • Co-expression with chaperones or foldases to improve folding efficiency

• Purification Strategy:

  • Multi-step purification approach combining different chromatographic techniques

  • Immobilized metal affinity chromatography (IMAC) for initial capture

  • Ion-exchange chromatography for intermediate purification

  • Reversed-phase HPLC for final polishing and separation of correctly folded species

  • Size-exclusion chromatography to eliminate aggregates and misfolded species

• Quality Assessment:

  • Mass spectrometry to confirm molecular weight and cyclization

  • Circular dichroism to assess secondary structure

  • NMR spectroscopy for tertiary structure confirmation

  • Bioactivity assays to verify functional integrity

Implementation of this comprehensive approach can significantly improve both the yield and purity of recombinant Vodo peptides, facilitating their application in various research contexts.

How do sequence variations in intercysteine loops affect Vodo peptide bioactivity?

The intercysteine loops of Vodo peptides represent regions of significant sequence variation that directly influence their bioactivity profiles:

These sequence variations across the identified Vodo peptides (P1-P7) contribute to their diverse bioactivities, ranging from antimicrobial and insecticidal to immunomodulatory properties. Understanding these structure-function relationships is essential for rational design of recombinant Vodo peptide variants with enhanced or targeted activities.

What roles do the conserved cysteine residues play in Vodo peptide stability and function?

The six conserved cysteine residues in Vodo peptides are fundamental to their exceptional stability and structural integrity:

• Disulfide Connectivity Pattern:

  • The characteristic cysteine knot involves three disulfide bonds (Cys1-Cys4, Cys2-Cys5, Cys3-Cys6)

  • This arrangement creates a compact, knotted structure resistant to thermal, chemical, and enzymatic degradation

  • The disulfide pattern is preserved across all identified Vodo peptides despite sequence variations in other regions

• Structural Stabilization:

  • The cysteine knot creates a rigid core scaffold that constrains peptide flexibility

  • This stabilization allows loops to adopt precise conformations for target interaction

  • Thermal stability typically exceeds 100°C without denaturation

• Functional Implications:

  • Protection against proteolytic degradation in biological environments

  • Enhanced bioavailability compared to linear peptides

  • Extended half-life in circulation and tissues

  • Oral bioavailability potential due to resistance to digestive enzymes

• Evolutionary Conservation:

  • The consistent presence of these cysteine residues across diverse cyclotides suggests strong evolutionary selection

  • Conservation despite convergent evolution indicates their critical functional importance

The exceptional stability conferred by these conserved cysteines makes Vodo peptides particularly valuable as potential therapeutic agents and molecular scaffolds for bioengineering applications.

How can structural modifications enhance specific functions of recombinant Vodo peptides?

Strategic structural modifications of recombinant Vodo peptides can enhance targeted functions while maintaining their inherent stability:

• Loop Grafting Approaches:

  • Replacement of specific loops with bioactive sequences from other peptides

  • Preservation of the cysteine knot framework as a stable scaffold

  • Selection of appropriate loops for modification based on surface exposure and flexibility

• Point Mutations:

  • Introduction of charged residues to modify membrane interactions

  • Incorporation of unnatural amino acids for enhanced stability or novel functions

  • Conservative substitutions to fine-tune bioactivity while maintaining folding

• Chemical Conjugation:

  • Site-specific attachment of functional moieties (fluorophores, PEG, etc.)

  • Conjugation at non-critical residues to preserve bioactivity

  • Development of cyclotide-drug conjugates for targeted delivery

• Cyclization Variants:

  • Modification of the cyclization point in loop 6

  • Alterations in cyclization chemistry for improved production efficiency

  • Engineering of protease-specific cleavage sites for conditional activation

These modification strategies have been applied to cyclotides from various sources and can be specifically tailored for Vodo peptides to enhance their utility in diverse research and therapeutic applications. Sequence diversity wheels and homology modeling provide valuable guidance for selecting modification sites that minimize disruption of critical structural elements .

What therapeutic applications are being investigated for recombinant Vodo peptides?

Recombinant Vodo peptides are being explored for diverse therapeutic applications, leveraging their exceptional stability and structural adaptability:

• Antimicrobial Applications:

  • Activity against multidrug-resistant bacterial pathogens

  • Membrane-disrupting mechanisms that limit resistance development

  • Potential as topical or systemic antimicrobial agents

  • Synergistic effects with conventional antibiotics

• Cancer Therapeutics:

  • Selective cytotoxicity against certain cancer cell lines

  • Anti-angiogenic properties that inhibit tumor vascularization

  • Potential as drug delivery vehicles for cancer-targeting conjugates

  • Adjuvant therapy to enhance conventional chemotherapy

• Immunomodulatory Applications:

  • Anti-inflammatory effects in various disease models

  • Modulation of cytokine production and immune cell function

  • Potential applications in autoimmune disorders

  • Adjuvant properties for vaccine development

• Neuroprotective Agents:

  • Blood-brain barrier penetration capabilities

  • Protection against neurodegenerative processes

  • Potential applications in Alzheimer's and Parkinson's disease

  • Neurotrophic factor delivery vehicles

The structural diversity observed in the Vodo peptide family (P1-P7) provides a rich source of templates for developing specialized therapeutic agents with optimized pharmacological properties . Their recombinant production facilitates systematic modification and optimization for specific therapeutic targets.

How can structural characterization techniques be advanced for complex cyclotides like Vodo peptides?

Advanced structural characterization of complex cyclotides like Vodo peptides requires innovative methodological approaches:

• Enhanced Mass Spectrometry Techniques:

  • Ion mobility MS for conformational analysis of intact cyclotides

  • Electron transfer dissociation (ETD) for improved fragmentation patterns

  • Top-down proteomics approaches for direct analysis of intact cyclotides

  • Native MS to study cyclotide-target interactions

• Advanced NMR Methodologies:

  • Residual dipolar coupling measurements for refined structure determination

  • Paramagnetic relaxation enhancement to probe surface accessibility

  • Hydrogen-deuterium exchange to assess structural dynamics

  • Solid-state NMR for membrane-associated conformations

• Integrated Computational Approaches:

  • Molecular dynamics simulations with specialized force fields for cyclotides

  • Machine learning algorithms for structure prediction from sequence

  • Quantum mechanical calculations of disulfide bond geometries

  • Virtual screening for target binding prediction

• High-Resolution Imaging:

  • Cryo-electron microscopy for cyclotide-receptor complexes

  • Atomic force microscopy for membrane interaction studies

  • Super-resolution microscopy to track labeled cyclotides in biological systems

These advanced techniques can provide unprecedented insights into the structure-function relationships of Vodo peptides, informing rational design strategies for engineered variants with enhanced properties. Protein diversity wheel analysis has already revealed important sequence variations among cyclotides that can be further explored using these methods .

What are the key considerations for designing recombinant Vodo peptide libraries for drug discovery?

Designing effective recombinant Vodo peptide libraries for drug discovery requires careful consideration of several key factors:

• Diversity Strategy:

  • Focus on variable regions (loops) while maintaining the conserved cysteine framework

  • Implement site-directed mutagenesis at specific positions known to influence bioactivity

  • Consider combinatorial approaches targeting multiple loops simultaneously

  • Include both conservative and non-conservative substitutions to explore structure-activity space

• Library Construction Methodology:

  • DNA shuffling between different Vodo peptide templates

  • Split-intein circular ligation for cyclized library generation

  • Golden Gate assembly for efficient combinatorial library creation

  • In vitro transcription/translation systems for rapid screening

• Screening Platform Design:

  • Development of high-throughput assays relevant to the target indication

  • Cell-based reporter systems for specific pathway modulation

  • Phenotypic screening approaches for complex disease models

  • Affinity selection methods against specific molecular targets

• Iterative Optimization:

  • Sequential rounds of selection and diversification

  • Machine learning to guide library design based on initial screening results

  • Structure-guided optimization using computational models

  • Pharmacokinetic and stability assessment of lead candidates

The successful implementation of these considerations can yield diverse libraries of recombinant Vodo peptides with novel bioactivities and improved drug-like properties. The natural diversity observed in cyclotides from V. odorata provides an excellent starting point for such library designs, as evidenced by the structural variation in the Vodo P1-P7 peptides .

How can misfolding issues in recombinant Vodo peptide production be resolved?

Misfolding represents a significant challenge in recombinant Vodo peptide production that can be addressed through several strategic approaches:

• Optimizing Redox Conditions:

  • Implement controlled glutathione redox systems (GSH/GSSG ratios of 1:1 to 1:10)

  • Utilize specialized redox buffers designed for disulfide-rich proteins

  • Conduct folding under dilute conditions to minimize intermolecular interactions

  • Explore temperature ramping protocols during the folding process

• Chaperone Co-expression Strategies:

  • Co-express with disulfide isomerases (PDI, DsbC) to facilitate correct disulfide pairing

  • Incorporate molecular chaperones (GroEL/ES, DnaK/J) to prevent aggregation

  • Utilize specialized folding catalysts specific to cyclic peptides

  • Engineer fusion to chaperone-like domains with subsequent precision cleavage

• Fusion Partner Optimization:

  • Select fusion partners known to enhance solubility (SUMO, thioredoxin, MBP)

  • Position the fusion partner to minimize steric hindrance to cyclization

  • Incorporate flexible linkers to facilitate native-like folding

  • Design cleavage sites that leave minimal or no residual amino acids

• Analytical Monitoring:

  • Implement real-time folding monitoring using fluorescent probes

  • Utilize reversed-phase HPLC to distinguish folding intermediates

  • Apply mass spectrometry to track disulfide bond formation

  • Develop bioactivity assays as functional verification of correct folding

These approaches can significantly improve the production of correctly folded recombinant Vodo peptides, enhancing both yield and biological activity for research applications.

What strategies can address low expression yields of recombinant Vodo peptides?

Low expression yields of recombinant Vodo peptides can be improved through comprehensive optimization strategies:

• Expression Vector Engineering:

  • Codon optimization based on expression host preferences

  • Selection of strong but controllable promoters (T7, AOX1, GAL1)

  • Incorporation of optimal ribosome binding sites or Kozak sequences

  • Integration of multiple copy numbers for increased gene dosage

• Host Strain Selection and Modification:

  • Utilize specialized strains designed for disulfide-rich proteins

  • Consider strains with reduced protease activity

  • Implement hosts with enhanced secretory capacity for extracellular expression

  • Engineering of chaperone overexpression in production strains

• Culture Condition Optimization:

  • Temperature modulation (typically 16-25°C for improved folding)

  • Optimize induction timing and inducer concentration

  • Implement fed-batch or continuous cultivation strategies

  • Supplement media with folding enhancers (glycerol, arginine)

• Purification Process Optimization:

  • Develop specialized purification protocols for cyclotides

  • Implement on-column refolding techniques

  • Utilize affinity tags with minimal impact on folding

  • Optimize elution conditions to maximize recovery

These strategies, often implemented in combination, can significantly improve the expression yields of recombinant Vodo peptides from initial milligram scales to levels suitable for comprehensive research applications and potential therapeutic development.

How can cyclization efficiency be improved in recombinant Vodo peptide production?

Improving cyclization efficiency represents a critical challenge in recombinant Vodo peptide production that can be addressed through several specialized approaches:

• Enzymatic Cyclization Methods:

  • Utilize asparaginyl endopeptidases (AEPs) that naturally facilitate cyclization in plants

  • Implement sortase-mediated ligation with optimized recognition sequences

  • Apply butelase-1, a highly efficient cyclization enzyme from Clitoria ternatea

  • Engineer recombinant peptide sequences with optimal recognition motifs for these enzymes

• Intein-Based Approaches:

  • Implement split-intein circular ligation of peptides and proteins (SICLOPPS)

  • Optimize intein selection based on efficiency with cyclotide sequences

  • Incorporate mutations in inteins to enhance splicing efficiency

  • Design junction sequences to minimize steric hindrance to splicing

• Chemical Ligation Strategies:

  • Native chemical ligation between C-terminal thioester and N-terminal cysteine

  • Expressed protein ligation combining recombinant production with chemical cyclization

  • Implement solid-phase approaches for smaller cyclotides

  • Develop specialized protecting group strategies for selective cyclization

• Cyclization Monitoring and Optimization:

  • Develop real-time assays for cyclization efficiency

  • Implement LC-MS/MS methods to distinguish linear and cyclic forms

  • Optimize buffer conditions, temperature, and pH for cyclization reactions

  • Reduce competing reactions through careful reaction control

These methodologies can significantly improve the cyclization efficiency of recombinant Vodo peptides, increasing the yield of correctly processed final products with authentic circular backbones essential for their stability and bioactivity.

What intellectual property considerations are important for recombinant Vodo peptide research?

Navigating intellectual property (IP) considerations is essential for researchers working with recombinant Vodo peptides:

• Patent Landscape Analysis:

  • Conduct comprehensive searches of existing patents covering:
    a) Natural cyclotides from Viola odorata
    b) Recombinant expression methods for cyclotides
    c) Specific applications of cyclotide-based therapeutics
    d) Methods for cyclization and structural modification

  • Evaluate freedom-to-operate in intended research directions

  • Identify potential licensing requirements for technology platforms

• Patentability Considerations:

  • Novel recombinant Vodo peptides with specific sequence modifications

  • New methods for efficient cyclization or expression

  • Novel applications with demonstrated efficacy

  • Formulations that enhance stability or delivery

  • Combinations with other therapeutic agents

• Research Collaboration Agreements:

  • Clearly define ownership of new inventions

  • Establish publication rights and review procedures

  • Develop material transfer agreements for peptide sharing

  • Implement confidentiality provisions for unpublished data

• Commercialization Pathways:

  • Evaluate direct patent filing versus defensive publication strategies

  • Consider orphan drug designation for rare disease applications

  • Develop strategic positioning versus other peptide therapeutics

  • Assess territory-specific protection needs

These considerations help researchers navigate the complex IP landscape surrounding recombinant Vodo peptides while maximizing protection for novel discoveries and ensuring compliance with existing rights.

How can standardized evaluation methods be developed for comparing different recombinant Vodo peptides?

Standardized evaluation methods are essential for reliable comparison of different recombinant Vodo peptides across research groups:

• Structural Characterization Standards:

  • Consensus protocols for circular dichroism spectroscopy

  • Standardized NMR assignment and structure calculation approaches

  • Uniform MS/MS fragmentation and analysis parameters

  • Validated methods for disulfide bond mapping and confirmation

• Functional Assay Standardization:

  • Reference compounds and positive controls for each assay type

  • Detailed standard operating procedures with defined acceptance criteria

  • Inter-laboratory validation of key bioactivity assays

  • Dose-response relationship reporting with standard metrics (EC50, IC50)

• Production Quality Metrics:

  • Purity assessment using multiple orthogonal methods

  • Endotoxin testing protocols for research-grade peptides

  • Stability testing under standardized conditions

  • Batch-to-batch consistency evaluation parameters

• Data Reporting Framework:

  • Comprehensive checklist of minimum required characterization data

  • Standardized formats for sequence and structural data

  • Central repository for recombinant cyclotide characterization

  • Consistent nomenclature system for novel peptides

Implementation of these standardized evaluation methods would significantly enhance the reproducibility and comparability of research on recombinant Vodo peptides, accelerating progress in the field and facilitating more effective collaboration between research groups studying these complex macrocyclic peptides.

What research consortia or collaborative networks exist for cyclotide researchers?

The field of cyclotide research, including work on Vodo peptides, benefits from several collaborative networks and resources:

• Academic Research Consortia:

  • The International Cyclotide Consortium (ICC) connects researchers across multiple continents

  • Plant Peptide Research Network coordinates efforts on plant-derived peptides including cyclotides

  • Therapeutic Peptide Accelerator Consortium includes cyclotides as a focus area

  • Various regional networks in Australia, Europe, and Asia dedicated to cyclotide research

• Collaborative Research Platforms:

  • CyBase: Online database of cyclotide sequences and structures

  • Peptide Atlas: Repository including cyclotide mass spectrometry data

  • BioModels Database: Contains structural models of cyclotides

  • PDB: Houses experimentally determined cyclotide structures

• Technology Transfer Partnerships:

  • Academic-industrial collaborations for scale-up production

  • Cyclotide-focused biotechnology startups

  • Pharmaceutical partnerships for therapeutic development

  • Agricultural research collaborations for pest management applications

• Funding and Resource Sharing Mechanisms:

  • Material transfer agreements specific to cyclotide research

  • Specialized grant programs for peptide-based therapeutics

  • Core facilities with expertise in cyclotide analysis

  • Collaborative training programs for early career researchers

Engaging with these research networks provides cyclotide researchers with access to specialized expertise, shared resources, and collaborative opportunities that can accelerate progress in recombinant Vodo peptide research and facilitate translation to practical applications.